Navigation Links
NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
Date:7/24/2008

SOPHIA ANTIPOLIS, France, July 24 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the top-line results from the 52-week open label safety extension that was conducted following the completion of the 301 phase 3 study for naproxcinod. The results revealed no unexpected safety findings and efficacy was maintained for the one-year duration of the study, as measured by the patients' global assessment scale. In addition, the results showed that the patients' mean blood pressure was stable for 52 weeks following the completion of the 301 study, suggesting that naproxcinod does not increase blood pressure over time. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) class, which NicOx is developing for the treatment of the signs and symptoms of osteoarthritis.

The 301 safety extension study was conducted in 92 clinical centers in the United States and enrolled the first 500 eligible patients with osteoarthritis of the knee who successfully completed the 301 phase 3 study for naproxcinod (see press releases of June 13, 2008 and November 12, 2007). NicOx expects to announce the top-line efficacy results from the ongoing 302 and 303 pivotal phase 3 studies for naproxcinod in the second half of 2008, ahead of a projected New Drug Application (NDA) in mid-2009.

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "The data from this open label trial form an important part of our long term safety database for naproxcinod. We are happy with the good overall safety we have observed in this study and look forward to gaining further 52 week data from the 302 study, which includes an active control arm."

The 302 study is being conducted in patients with osteoarthritis of the knee and efficacy is being measured at 13 weeks by the same three co-primary endpoints as in the 301 and 303 studies. In addition, th
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
6. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
7. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
8. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
9. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
10. NicOx Naproxcinod ABPM Data Presented at American Heart Association
11. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... and LONDON , August 28, 2015 /PRNewswire/ ... approach seamlessly connects people, technologies and ... improving outcomes and the cost of healthcare ... AEX: PHIA) today announced its presence at  ESC Congress 2015 ... including Heart Model A.I. , EchoNavigator and IntelliSpace Cardiovascular, that ...
(Date:8/27/2015)... 2015  A recent study by Feucht et ... the Arthrosurface HemiCAP® Wave implant, which is based ... design implant for isolated patellofemoral disease. While both ... pain scores, none of the patients in the ... 53% of the patients in the "onlay" group, ...
(Date:8/27/2015)... RIVERSIDE, Calif. , Aug. 27, 2015 /PRNewswire/ ... important milestone in the commercial development of the ... . The Smart Oxygen device, being developed by ... adjusts to a patient,s changing demand for oxygen ... that the 510 (k) submission for the Smart ...
Breaking Medicine Technology:Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... 8, 2011 Reportlinker.com announces that a new ... Europe Drug Delivery Devices Market ... Europe Drug Delivery Devices Market ... GlobalData,s new report, "Europe Drug Delivery ...
... June 8, 2011 Edison Pharmaceuticals, Inc. announced ... has granted orphan drug designation to EPI-743 for ... these mitochondrial diseases affect an estimated 60,000 individuals. ... 1982, provides incentives for companies to pursue treatments ...
Cached Medicine Technology:Reportlinker Adds Europe Drug Delivery Devices Market Outlook to 2017 2Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation 2
(Date:8/29/2015)... ... August 29, 2015 , ... People who have heart or ... or asthma, are at higher risk from wildfire smoke especially in Calgary, Alberta.Those ... heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive to air pollution. ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
(Date:8/28/2015)... ... August 28, 2015 , ... An online provider of CPAP machines, masks, supplies, ... CPAP equipment more affordable by offering shipping at no cost to you, directly to ... orders of any size. My Cpap Store is located in Las Vegas, Nevada. , ...
(Date:8/28/2015)... ... 28, 2015 , ... An article published August 19th by the ... gone through to open a pizzeria in Westchester. Mr. LaRocco was aware from opening ... months, but the current process, having already gone on for over a year, is ...
(Date:8/28/2015)... Falls Church, VA (PRWEB) , ... ... ... and Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and ... – Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... ventromedial prefrontal cortex may be associated with how people ... event.// ,Researchers from Massachusetts General Hospital have ... factor that affects the incidence of people developing anxiety ... , ,People who go through an intense and ...
... death was reported after being given an unauthorized Hepatitis A ... province of Anhui were administered the Hepatitis A vaccine on ... ,Li Wei a six-year-old child suffered an unspecified infection ... following which she died a few days later. Some of ...
... risk of cellular rejection after a heart transplant// ... ,The drug, a humanized monoclonal antibody, is directed ... ,Patients who were taken into the Study ... ,The primary endpoint was a composite of moderate ...
... 75 million people in the United States, Europe and Japan ... recommended that drinking calcium water may help in reducing osteoporosis., ... majority of the people do not consume enough of this ... individuals with osteoporosis but for many teenagers, and those in ...
... People who remain angry for considerable periood of time may ... ,Reserachers of University of California, Berkeley, had found that feeing ... like lowering of the immune functions, urge to pick up ... life. ,Reserachers who had done a survey of the ...
... consumption of fruits, vegetables and foods high in fibre can ... heart disease. ,Western cuisines are not so high in ... in the diet. ,10 healthy individuals were taken as ... of them. The diets were a vegetarian diet rich in ...
Cached Medicine News:Health News:Fibre Rich Food A Boon For Lowering Cholesterol 2
... Innovators in Anesthesia and Respiratory Products, ... medical devices for Anesthesia and Respiratory professionals. ... products that enhance the clinician's ability to ... attention to the bottom line. , ...
... Innovators in Anesthesia and Respiratory Products, ... quality medical devices for Anesthesia and Respiratory ... manufacture products that enhance the clinician's ability ... close attention to the bottom line. , ...
... optimum lung penetration for maximum therapeutic benefit. ... µ at 6-8 LPM. Latex-free components. Usable ... the world leader in airway management products, ... proven technology by offering top brands in ...
... makeshift, modified nebulizer setups to deliver CNT ... when your patient is critical? OMNI~MAX has ... in Heliox rescue therapy. In severe obstructive ... standard of care in hospitals across the ...
Medicine Products: